Search MRMD
MARIMED INC.
OTC · CIK 1522767
Last close0.07
Daily change-0.00 (-1.43%)
10 Years gain-44.80%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
MRMD · STANDARD
SIC 2833 · Medicinal Chemicals & Botanical Products · Fiscal year end 1231
Fundamental
14.5Momentum
60.8Acceleration
60.9Confidence
91.0Annual Revenue15
Quarterly Revenue60
Annual CFO15
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth3.3 / 25
Quality4.7 / 25
Capital Efficiency1.6 / 20
Balance Sheet1.8 / 15
Shareholder Economics2.4 / 10
Forward Indicators0.0 / 5
Signals
Gross margin expansionGross margin improved by 0.6248 percentage points.
Operating leverageOperating margin improved by 2.1575 percentage points.
ROIC expansionROIC improved by 2.2306 percentage points.
Key Metrics
Revenue Growth TTM2.53%OK
Revenue CAGR 3Y6.05%OK
Gross Margin39.46%OK
Operating Margin1.95%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC2.03%OK
Incremental Operating Margin 3Y-62.26%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y4.45%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $159.83M | $57.88M | -$2.82M | $7.70M | $6.53M | 36.22% | -1.76% | 4.08% | -1.81% | 390.14M |
| 2025 FY Dec 31, 2024 | $157.71M | $62.61M | $2.61M | $6.79M | -$5.18M | 39.7% | 1.65% | -3.28% | 2.25% | 379.15M |
| 2024 FY Dec 31, 2023 | $148.60M | $65.92M | $14.39M | $7.91M | -$12.22M | 44.36% | 9.68% | -8.22% | 22.37% | 363.4M |
| 2023 FY Dec 31, 2022 | $134.01M | $63.96M | $20.37M | $7.31M | -$4.83M | 47.73% | 15.2% | -3.6% | 52.83% | 380.29M |
| 2022 FY Dec 31, 2021 | $121.46M | $66.26M | $26.86M | $35.86M | $17.98M | 54.55% | 22.12% | 14.8% | 74.6% | 372.4M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $161.68M | sum latest 4 fiscal quarters Revenue | OK | 0001522767-26-000167, 0001522767-25-000224 |
| Revenue Growth TTM | 2.53% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001522767-26-000167, 0001522767-25-000224 |
| Revenue CAGR 3Y | 6.05% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001522767-26-000030 |
| Revenue CAGR 5Y | 25.72% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001522767-26-000030 |
| Gross Profit CAGR 3Y | -3.27% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001522767-26-000030 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001522767-26-000167, 0001522767-25-000224 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 39.46% | Gross Profit / Revenue | OK | 0001522767-26-000167, 0001522767-25-000224 |
| Operating Margin | 1.95% | Operating Income / Revenue | OK | 0001522767-26-000167, 0001522767-25-000224 |
| ROIC | 2.03% | NOPAT / Average Invested Capital | OK | 0001522767-26-000167, 0001522767-25-000224 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001522767-26-000167 |
| Current Ratio | 0.92x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 0.1x | (Cash + Short-term Investments) / Total Debt | OK | 0001522767-26-000167 |
| Revenue per Diluted Share | $0.40 | Revenue / Diluted Shares | OK | 0001522767-26-000167, 0001522767-25-000224 |